Matthew L Hirsch
Overview
Explore the profile of Matthew L Hirsch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
1151
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Song L, Hasegawa T, Brown N, Bower J, Samulski R, Hirsch M
Nucleic Acids Res
. 2025 Jan;
53(3).
PMID: 39868534
Adeno-associated virus (AAV) inverted terminal repeats (ITRs) induce p53-dependent apoptosis in human embryonic stem cells (hESCs). To interrogate this phenomenon, a synthetic ITR (SynITR), harboring substitutions in putative p53 binding...
2.
Young K, Hasegawa T, Vridhachalam N, Henderson N, Salmon J, McCall T, et al.
Mol Ther Methods Clin Dev
. 2024 Dec;
32(4):101360.
PMID: 39703903
Non-infectious uveitis (NIU) is a painful recurrent disease affecting 2%-5% of horses. Current treatments require frequent administration with associated adverse events. In a previous study, intravitreal (IVT) adeno-associated virus (AAV)...
3.
Gilger B, Hasegawa T, Sutton R, Bower J, Li C, Hirsch M
Mol Ther
. 2024 Sep;
32(11):4006-4020.
PMID: 39245940
Corneal blindness affects more than 5 million individuals, with over 180,000 corneal transplantations (CTs) performed annually. In high-risk CTs, almost all grafts are rejected within 10 years. Here, we investigated...
4.
Nilles J, Roberts D, Salmon J, Song L, ODea C, Marjoram L, et al.
Mol Ther Methods Clin Dev
. 2023 Apr;
29:227-235.
PMID: 37090476
Ocular graft versus host disease (OGvHD) develops after allogeneic hematopoietic stem cell transplantation (HSCT) and manifests as ocular surface inflammatory disease. This study evaluated the efficacy of adeno-associated virus (AAV)...
5.
Crabtree E, Uribe K, Smith S, Roberts D, Salmon J, Bower J, et al.
PLoS One
. 2022 Aug;
17(8):e0270972.
PMID: 35980983
Equine recurrent uveitis (ERU) is a spontaneous, painful, and vision threatening disease affecting up to 25% of equine populations worldwide. Current treatments of ERU are non-specific and have many side...
6.
Gilger B, Hirsch M
Int J Mol Sci
. 2022 Apr;
23(7).
PMID: 35408825
The purpose of this paper is to review human leukocyte antigen G (HLA-G) in the eye, its role in immune tolerance, and the potential therapeutic use of AAV gene transfer...
7.
Bower J, Song L, Bastola P, Hirsch M
Viruses
. 2021 Jul;
13(7).
PMID: 34201599
Adeno-associated virus (AAV) was first characterized as small "defective" contaminant particles in a simian adenovirus preparation in 1965. Since then, a recombinant platform of AAV (rAAV) has become one of...
8.
Song L, Samulski R, Hirsch M
Hum Gene Ther
. 2020 Aug;
31(19-20):1054-1067.
PMID: 32829671
Recombinant adeno-associated viral (rAAV) vector mobilization is a largely theoretical process in which intact AAV vectors spread or "mobilize" from transduced cells and infect additional cells within, or external of,...
9.
Bastola P, Song L, Gilger B, Hirsch M
Pharmaceutics
. 2020 Aug;
12(8).
PMID: 32823625
According to the World Health Organization, corneal diseases are the fourth leading cause of blindness worldwide accounting for 5.1% of all ocular deficiencies. Current therapies for corneal diseases, which include...
10.
Song L, Bower J, Hirsch M
Methods Mol Biol
. 2020 Jun;
2145:77-102.
PMID: 32542602
Gene delivery approaches using adeno-associated virus (AAV) vectors are currently the preferred method for human gene therapy applications and have demonstrated success in clinical trials for a diverse set of...